No fanfare or madness, but a good debut for Luka Doncic after more than a month out, and where LeBron demanded authenticity on the court.

The ASX dropped as CSL slumped on low US vaccine take up, gold miners soared and consumer sentiment stayed flat.

"But I think what the street was expecting and what investors were generally hoping for was that they would take guidance up a little bit, especially ... down with Gates to drill into the book ...

Vertex just won approval for a drug to treat ... according to a Society of Actuaries report. First, a bit of background on the pain-drug environment in the U.S. so far. Options have been limited ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.

Next: Access Our New, Shockingly Simple 'Alert System' RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients ...

Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain.

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...